8-KEarnings & ResultsExhibits & Filings

PFIZER INC 8-K Report, Financial Results (Jul 29, 2014)

Filed July 29, 2014For Securities:PFE

Summary

Pfizer Inc. (PFE) filed an 8-K on July 29, 2014, to report its financial results for the second quarter of 2014. The core of this filing is the press release, attached as Exhibit 99, which details the company's performance during the period. While the 8-K itself is brief, it serves as the official mechanism to incorporate the comprehensive Q2 2014 earnings information into the public record, making it accessible to investors and the market. Investors should refer to the press release (Exhibit 99) for specific financial data, including revenue, earnings per share, and segment performance. This filing signals the official disclosure of Pfizer's Q2 2014 financial outcomes, providing critical data points for evaluating the company's operational health and strategic progress during that quarter.

Key Highlights

  • 1Pfizer Inc. announced its second quarter 2014 financial results via an 8-K filing on July 29, 2014.
  • 2The primary content of the filing is a press release (Exhibit 99) detailing the Q2 2014 financial performance.
  • 3The press release is officially incorporated by reference into the 8-K filing.
  • 4Investors can find detailed financial information, including operational results and condition, within the attached press release.
  • 5The filing serves as formal notification and public dissemination of Pfizer's Q2 2014 financial outcomes.
  • 6Atiba D. Adams, Vice President and Corporate Secretary, signed the report on behalf of Pfizer.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report Pfizer Inc.'s financial results for the second quarter of 2014. It incorporates a press release containing these results as an exhibit.

The detailed financial results for Q2 2014 are contained within the press release, which is included as Exhibit 99 to this 8-K filing. Investors should consult this press release for specific figures.

This 8-K filing primarily serves to report historical financial results for the second quarter of 2014. It does not, based on the provided text, introduce new strategic initiatives or forward-looking guidance; that information would typically be found in the referenced press release.

Exhibit 99, the press release dated July 29, 2014, is significant because it contains the official and detailed financial results for Pfizer's second quarter of 2014. By filing it as part of the 8-K, the information is formally recognized and incorporated into the company's SEC filings.